# NUVAXOVID: POWERFUL AGAINST COVID-19, GENTLE ON PATIENTS.[1]

## The non-mRNA COVID-19 Vaccine With Manageable Side Effects.[1]*

NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NUVAXOVID is approved for use in individuals who are:

- 65 years of age and older, or
- 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

## **NUVAXOVID** is the ONLY non-mRNA, protein-based COVID-19 vaccine[1,2]

**Protein-based**
NUVAXOVID directly provides the protein needed for antibody production[1,2]

**Recombinant**
Developed using technology already present in modern flu vaccines[1,3]

**Adjuvanted**
The potent adjuvant provides a robust and enhanced immune response[1,4]

## What makes **NUVAXOVID** different from mRNA COVID-19 vaccines?

### How **NUVAXOVID** Builds Immunity[2]:

**STEP 1**

Spike proteins contained in the vaccine are recognized by the immune system

**STEP 2**

Immune system produces antibodies and activates other immune cells

### How **mRNA Vaccines** Build Immunity[2]:

**STEP 1**

mRNA uses cells' machinery to make the spike protein

**STEP 2**

Cells display spike protein antigens on their surface, where it is recognized by the immune system

**STEP 3**

Immune system produces antibodies and activates other immune cells

## Who can receive **NUVAXOVID**?

Patients aged 65+ AND patients aged 12-64 who have ≥1 underlying condition that puts them at high risk for severe outcomes from COVID-19. NUVAXOVID can be used as a primary series OR seasonal dose following vaccination with any approved COVID-19 vaccine.[1]

*In the pivotal clinical trial, most common side effects were mild-to-moderate and ≤0.1% of patients experienced Grade 4 solicited adverse reactions.[1]

**CPT Code 91304** Use this CPT code when administering NUVAXOVID to ensure you receive proper payment. This CPT code is unique to NUVAXOVID – the ONLY non-mRNA COVID-19 vaccine.[1,2]

## IMPORTANT SAFETY INFORMATION

**CONTRAINDICATION**

Do not administer NUVAXOVID to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of NUVAXOVID or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of NUVAXOVID

**Please see additional Important Safety Information on back page.**
**Please see the full Prescribing Information here.**

Nuvaxovid®
(COVID-19 Vaccine, Adjuvanted)

# COULD OFFERING YOUR PATIENTS A non-mRNA COVID-19 VACCINE **MAKE THE DIFFERENCE?**

### NUVAXOVID OFFERS **POWERFUL PROTECTION** AGAINST COVID-19[1,5]

**~90%**

**Efficacy preventing COVID-19 in the pivotal trial**

**Primary endpoint:** efficacy in preventing PCR-confirmed symptomatic mild, moderate, or severe COVID-19 from 7 days after the second dose.

(95% CI: 82.5, 93.8; $p<0.001$) N=25,510

### **ZERO** NUVAXOVID PATIENTS HAD MODERATE-TO-SEVERE COVID-19 ILLNESS[1,5]

**100%**

**Protection from moderate-to-severe COVID-19†**

**Secondary endpoint:** efficacy in preventing moderate-to-severe disease from then-circulating strains of virus.

(95% CI: 87.0, 100.0) N=25,452

The NUVAXOVID vaccine may not protect all participants.

**Pivotal Trial Study Design:** Phase 3, multicenter, randomized, observer-blinded, placebo-controlled clinical trial evaluating efficacy and safety in 29,943 adults aged 18 and older. Participants were stratified by age (18 to 64 years and ≥65 years) and assigned in a 2:1 ratio to receive NUVAXOVID or placebo. Data based on strains circulating at time of study[1,5]

†Moderate disease was defined as high fever and objective evidence of lower respiratory tract infection. Severe COVID-19 was defined as the presence of clinically significant tachypnea, tachycardia, or hypoxia; receipt of intensive respiratory support; major dysfunction of one or more organ systems; admission to an intensive care unit; or death.[5]

## **NUVAXOVID** had low reactogenicity and minimal disruptive side effects[1]

In the pivotal clinical trial, the majority of adverse events were Grade 1 or 2 and did not prevent daily activities. Higher severity reactions (Grade 4) were experienced by ≤0.1% of patients for each of the most frequent solicited adverse reactions.[1]

**Discover more about the efficacy and tolerability of NUVAXOVID**

## INDICATION

NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). NUVAXOVID is approved for use in individuals who are:

- 65 years of age and older, or
- 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

## IMPORTANT SAFETY INFORMATION

**CONTRAINDICATION**

Do not administer NUVAXOVID to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of NUVAXOVID or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of NUVAXOVID

**MANAGEMENT OF ACUTE ALLERGIC REACTIONS**

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of NUVAXOVID

**MYOCARDITIS AND PERICARDITIS**

Clinical trials data provide evidence for increased risks of myocarditis and pericarditis following administration of NUVAXOVID. There have been post-marketing reports of myocarditis and pericarditis following administration of NUVAXOVID

**SYNCOPE**

Syncope (fainting) may occur in association with administration of injectable vaccines, including NUVAXOVID. Procedures should be in place to avoid injury from fainting

**ALTERED IMMUNOCOMPETENCE**

Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to NUVAXOVID

NUVAXOVID may not protect all vaccine recipients

**COMMON ADVERSE REACTIONS**

The most commonly reported (>10%) solicited adverse reactions included: injection site pain/tenderness, fatigue/malaise, muscle pain, headache, nausea/vomiting, fever, and joint pain

**Please see the full Prescribing Information here.**

**References: 1.** Nuvaxovid. Prescribing Information. Novavax, Inc. **2.** Centers for Disease Control and Prevention. Understanding how COVID-19 vaccines work. September 2024. Accessed September 18, 2025. https://www.cdc.gov/covid/vaccines/how-they-work.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Fdifferent-vaccines%2Fhow-they-work.html **3.** Cid R, Bolívar J. Platforms for production of protein-based vaccines: from classical to next-generation strategies. *Biomolecules.* 2021;11(8):1072. doi: 10.3390/biom11081072 **4.** Bengtsson KL, Song H, Stertman L, et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. *Vaccine.* 2016;34(16):1927-1935. doi:10.1016/j.vaccine.2016.02.033 **5.** Dunkle LM, Kotloff KL, Gay CL, et al; 2019nCoV-301 Study Group. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. *N Engl J Med.* 2022;386(6):531-543. doi: 10.1056/NEJMoa2116185

sanofi

MAT-US-2505042-v2.0-09/2025 

Sanofi 1 Discovery Drive, Swiftwater, Pennsylvania 18370 www.sanofi.us

Nuvaxovid® (COVID-19 Vaccine, Adjuvanted)